Abstract: Disclosed herein are methods for using dual amplification of MYC and HSF1 in cancer cells to identify cancer cells having increased susceptibility to a therapeutic inhibitor. Disclosed herein are methods for treating a patient with cancer where the cancer cells have coamplification of MYC and HSF1. Also disclosed are methods for identifying therapeutic target and therapeutic compounds by screening with cells known to have dual amplification of MYC and HSF1.

Abstract: A TAT-FXN fusion polypeptide useful in treating subjects diagnosed with Friedrich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.

Abstract: A charge detection mass spectrometer (CDMS) includes an electrostatic linear ion trap (ELIT), a processor, and a memory having instructions stored therein executable by the processor to (a) control the ELIT to trap an ion, (b) collect ion measurement information as the trapped ion oscillates back and forth through the ELIT, the ion measurement information including charge induced by the ion on a charge detector of the ELIT during each pass of the ion through the ELIT and timing of the induced charges relative to one another, (c) process the ion measurement information in the time-domain for each of a plurality of sequential time windows of the ion measurement information to determine a charge magnitude of the ion during each time window, and (d) determine the magnitude of charge of the trapped ion based on the charge magnitudes of each of the time windows.

Abstract: Embodiments herein report compositions, methods, uses and manufacturing procedures for rotavirus constructs and immunogenic compositions thereof. Some embodiments concern compositions that include, but are not limited to, chimeric rotaviruses of use in immunogenic compositions against rotavirus infection as well as against other pathogenic virus infection in a subject. In certain embodiments, constructs of use herein can be generated and used where a rotavirus expression system further includes one or more nucleic acid molecules encoding one or more polypeptides of another pathogen (e.g. another enteric or mucosal pathogen).

Abstract: An electrostatic linear ion trap (ELIT) array includes a plurality of ion mirrors and a plurality of elongated charge detection cylinders each defining an axial passageway centrally therethrough, the ion mirrors and the charge detection cylinders arranged relative to one another such that each charge detection cylinder is positioned between a different respective pair of the ion mirrors with the respective axial passageways of each coaxial with one another, wherein the axial passageways of the ELITs are not coaxial with one another, means for selectively directing at least one ion into each of the plurality of ELITs, and means for controlling each of the ion mirrors in a manner which causes the at least one ion in at least two of the ELITs to become trapped therein and to simultaneously oscillate back and forth between the respective ion mirrors each time passing through the respective charge detection cylinder.

Abstract: A TAT-FXN fusion polypeptide useful in treating subjects diagnosed with Friedrich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.

Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

Abstract: A charge detection mass spectrometer includes an ion trap configured to receive and store ions therein and to selectively release stored ions therefrom, and an electrostatic linear ion trap (ELIT) spaced apart from the ion trap, the ELIT including first and second ion mirrors and a charge detection cylinder positioned therebetween, and means for selectively controlling the ion trap to release at least some of the stored ions therefrom to travel toward and into the ELIT, and for controlling the first and second ion mirrors in a manner which traps in the ELIT a single one of the ions traveling therein and causes the trapped ion to oscillate back and forth between the first and second ion mirrors each time passing through and inducing a corresponding charge on the charge detection cylinder.

Abstract: A method of producing bioengineered tissue includes coating a microstructured fiber with a bioink containing a plurality of living cells. The microstructured fiber is embedded with microfluidic channels defining periodic outlet apertures, a plurality of ultrasonic transducers, at least one chemical sensor, and at least one temperature sensor. The method further includes applying the coated fiber to an anatomic model of an organ. The microfluidic channels and outlet apertures of the fiber are configured to function as an artificial blood-vessel system to the bioengineered tissue, thereby supplying building material for the proliferation of the plurality of living cells, and allowing the bioengineered tissue to mature into functional tissue.

Abstract: A caravanning vehicle system includes a lead vehicle having an engine and at least one trailing vehicle having an electric motor. The at least one trailing vehicle is non-mechanically connected to the lead vehicle. The lead vehicle includes a power transfer system that is configured to transfer electric power, wirelessly, to the at least one trailing vehicle.

Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

Abstract: A method of treating a Down syndrome (DS) subject with functional or at risk of decline of organ systems associated with accelerated aging due to over-production of H2S is disclosed. That method contemplates administering a pharmaceutical composition containing a H2S-reducing effective amount of hydrophilic polymer-substituted oxidized carbon nanoparticles (OCNPs) and an optional potentiating amount of lipoic acid or dihydrolipoic acid dissolved or dispersed in a physiologically acceptable diluent to the subject. The pharmaceutical composition can be administered parenterally as a liquid or per os as a solid or liquid.

Abstract: A thin film molecular memory is provided that satisfies criteria needed to make a molecular spintronic device, based on spin crossover complexes, competitive with silicon technology. These criteria include, device implementation, a low coercive voltage (less than 1V) and low write peak currents (on the order of 104 A/cm2), a device on/off ratio >10, thin film quality, the ability to “lock” the spin state (providing nonvolatility), the ability to isothermally “unlock” and switch the spin state with voltage, conductance change with spin state, room temperature and above room temperature operation, an on-state device resistivity less than 1 ?·cm, a device fast switching speed (less than 100 ps), device endurance (on the order of 1016 switches without degradation), and the ability of having a device with a transistor channel width of 10 nm or below.

Abstract: An improved nanocomposite cathode material for lithium-ion batteries comprising vanadium pentoxide substrates with a conductive matrix of graphene sheets and a network former such as silicon dioxide and a method of making the same.

Abstract: Disclosed herein are compounds that can act as inhibitors of nicotinamide phosphoribosyltransferase (“NAMPT”), and methods for their use in treating or preventing diseases, such as pulmonary arterial hypertension (“PAH”). The compounds described herein can include compounds of Formula (II) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

Abstract: This invention relates to pyrazolylacylpyrazoline compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat neurological disorders.

Abstract: The present disclosure provides “all-in-one” cartridges which contain necessary reagents and materials to isolate/preconcentrate targeted proteins from blood plasma and ionize them for mass spectrometry detection. In another configuration, the cartridges include proteolytic enzymes to digest the proteins into smaller peptides in addition to preconcentration and ionization for mass spectrometry detection.

Abstract: An audio signal encoding/decoding method and an apparatus for performing the same are disclosed. The audio signal encoding method includes obtaining a full-band input signal, extracting a first feature vector corresponding to a first sub-band signal and a second feature vector corresponding to a second sub-band signal using an encoder neural network including a plurality of encoding layers, generating a first code vector corresponding to the first feature vector and a second code vector corresponding to the second feature vector by compressing the first feature vector and the second feature vector, and generating a bitstream by quantizing the first code vector and the second code vector.

Abstract: A feeding analysis system reviews collected feeding data and provides analysis of data regarding nutritive sucking, feeding, and related activity.

Abstract: A method for analyzing charged particles may include generating, in or into an ion source region, charged particles from a sample of particles, causing the charged particles to enter a mass spectrometer from the ion source region at each of a plurality of differing physical and/or chemical conditions in a range of physical and/or chemical conditions in which the sample particles undergo structural changes, controlling the mass spectrometer to measure at least the charge magnitudes of the generated charged particles at each of the plurality of differing physical and/or chemical conditions, determining, with a processor, an average charge magnitude of the generated charged particles at each of the plurality of differing physical and/or chemical conditions based on the measured charge magnitudes, and determining, with the processor, an average charge magnitude profile over the range of physical and/or chemical conditions based on the determined average charge magnitudes.